POST Online Media Lite Edition



 

Pfizer to cease vaccine sales in China

Staff writer |
Pfizer is ceasing vaccine sales operations in China after the Chinese government failed to renew an import license for one of its products.

Article continues below






The company says that will cause a shortage of the treatment in China. Pfizer said in a statement that the license had expired for Prevenar, sold as Prevnar in the U.S. The vaccine protects toddlers against pneumococcal disease that can lead to pneumonia and other infections.

"Based on a careful assessment of this situation, we have decided to cease our Vaccines commercial operations in China at this time, effective immediately," the statement said. The vaccine is Pfizer’s No. 2-selling franchise globally, behind the Lyrica pain drug.

The vaccine operations will close immediately, affecting 200 employees who work in the division, a statement from the company said, adding that "most colleagues will be impacted" by the closure. Pfizer will help the affected employees find other positions within the company, the statement said.


What to read next

Pfizer thinking about consumer healthcare business sale
Pfizer officially withdraws from AstraZeneca deal
Pfizer to sell infusion business to ICU Medical